Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Microbiology & Immunology 2019

LabRoots and the Microbiology Planning Committee will bring the microbiology research community together at the 4th Annual Microbiology and Immunology Virtual Event! During the free, two-day event, participants will explore and discover new concepts, tools and techniques to apply to ongoing research and diagnostics.

Microbiology and Immunology cover an array of industries and disciplines, encompassing various research areas including pharmaceuticals, medicine, agriculture, and space. The development of new techniques and the ability to sequence organisms without the need to grow them in the laboratory has opened up a new world of microbial diversity and complexity we know little about.

Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.

Like the 2018 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots most

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2019 Microbiology and Immunology Virtual Event. Submission is free; submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 14 credits.

DiaSorin Molecular LLC manufactures and distributes molecular diagnostic products worldwide helping laboratories to streamline workflow and improve patient management.
Our Simplexa® molecular menu includes kits for HSV-1 & HSV-2, Flu A/B & RSV, Group A Strep, C. difficile and
...
Simplexa® controls. Our molecular menu also includes over 50 primer pairs and general purpose molecular reagents. All of our Direct assays require no sample extraction and provide results in about an hour.
Simplexa® products are designed for use on the LIAISON® MDX, a real-time PCR instrument. The instrument has the capability of running either an 8 well or 96 well disc providing an ideal platform to accommodate low to high volume testing needs. This allows users to leverage the system's flexibility and scalability to handle laboratory challenges.
We are a vendor partner to hospitals and reference laboratories that provides value through sales, service and support solutions.

As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new
...
world, and showed us how much further there is to go.

ATCC is the premier global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While
...
maintaining traditional collection materials, ATCC develops high quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological
...
samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

10x Genomics, Inc. is building tools for scientific discovery that reveal and address the true complexities of biology and disease. Through a combination of novel microfluidics, chemistry and bioinformatics, our award-winning Chromium System is enabling researchers around the
...
world to more fully understand the fundamentals of biology at unprecedented resolution and scale. Learn more at www.10xGenomics.com.

For 60 years The Baker Company has been at the forefront of engineering, testing and production of reliable laboratory contamination control equipment. Recognized as the industry pioneer, The Baker Company maintains an unparalleled passion for helping our customers advance
...
science, discovery, and clinical care.
The people of Baker have built that reputation by taking no chances with customers' safety and making no compromises when it comes to protecting the success of your research. Baker's laboratory products are built to order with precision craftsmanship and designed expressly for your unique application need. Our rigorous testing protocols go above and beyond what the average user would ever encounter and our quality control measures exceed industry standards. Our commitment to sustainable business practices and the development of a new generation of energy efficient products ensures that you - and your budget - will be pleased.

The American Biological Safety Association (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. The Association's goals are to provide a professional association that represents the
...
interests and needs of practitioners of biological safety, and to provide a forum for the continued and timely exchange of biosafety information.

Dr. Hollister is a microbial ecologist and bioinformaticist. She is interested in quantifying and characterizing microbial communities from a wide variety of environments, including the human body. Utilizing high throughput, next-generation DNA and RNA sequence approaches, her
...
research seeks to improve our understanding of microbial communities, their distribution across time and space, the ways in which they function, and their influence at broader scales. Dr. Hollister currently serves as the Director of Microbial Ecology and Bioinformatics for the Texas Children's Microbiome Center.

Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He
...
co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company's eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University.
Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator "Champion of Change." He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.

Neil Osheroff received a Bachelor's Degree in Chemistry from Hobart College in 1974 followed by a Ph.D. in Biochemistry and Molecular Biology from Northwestern University in 1979. His doctoral dissertation on the mechanism of action of cytochrome c was under the direction of
...
Professor Emanuel Margoliash.
Following his doctoral studies, Dr. Osheroff moved to the Stanford University School of Medicine in 1980, where he was a Helen Hay Whitney Foundation postdoctoral fellow with Dr. Douglas Brutlag in the Department of Biochemistry. In 1983, he moved to the Vanderbilt University School of Medicine as an Assistant Professor of Biochemistry and he has been on the faculty since that time. Dr. Osheroff currently holds Professorships in the Departments of Biochemistry and Medicine and was endowed with the John G. Coniglio Chair in Biochemistry in 2003. He has spent a combined 27 years on the editorial boards of The Journal of Biological Chemistry and Biochemistry and has authored over 240 publications.
Dr. Osheroff's research focuses on topoisomerases, enzymes that remove knots and tangles from the genetic material and modulate torsional stress in DNA. In addition to their critical physiological roles, human type I and II topoisomerases are the targets for a number of widely used anticancer drugs. Furthermore, bacterial type II topoisomerases are the targets for quinolones, a drug class that includes some of the most frequently prescribed antibacterials in the world. The Osheroff laboratory has made seminal contributions to our understanding of how topoisomerases function and how anticancer drugs, natural products, and antibacterials interact with these enzymes and alter their catalytic functions.
Beyond his research, Dr. Osheroff has a long-standing interest in mentoring and training young scientists and physicians. Twenty-seven Ph.D. students have graduated under his mentorship. Dr. Osheroff he has been a course director since 1990 and holds a number of educational leadership positions in the Vanderbilt University School of Medicine.
Dr. Osheroff Chaired the NCI-I "Transition to Independence" study section from 2013-2016 and has held leadership positions in two international medical science educator organizations.
Finally, Dr. Osheroff has received awards for mentoring, teaching, curricular design, educational service, and affirmative action and diversity. Over the past five years, he has been invited to present more than seventy scientific and educational talks at forty-six institutions/meetings in seventeen different countries.

Dr. Roossinck received a PhD in 1986 from the University of Colorado School of Medicine in Microbiology and Immunology, studying Hepatitis B virus, on an National Institutes of Health fellowship. Following a postdoctoral fellowship at Cornell University, where she began studying
...
plant viruses, she moved to the Samuel Roberts Noble Foundation as a principal investigator, and focused her research on plant virus evolution and ecology. After the discovery of a novel plant-fungus-virus three-way mutualistic symbiosis that allows plants to grow in geothermal soils in Yellowstone National Park her interests expanded to include viruses of fungi. Currently she is a member of the Center for Infectious Disease Dynamics, and a Professor of Virus Ecology, in the Department of Plant Pathology and Environmental Microbiology at the Pennsylvania State University. She and her team have been studying virus ecology and experimental evolution for 25 years using plant and fungal viruses as models, and have published a number of seminal papers in this area. She is an expert in virus diversity and biodiversity, and has done extensive work on complex interactions between beneficial viruses and their hosts that are involved in adaptation of plants and fungi to extreme environments.

Professor Emeritus John G. Thomas, PhD, is recognized as an "International Educator and Global
Microbiologist " (www.globalbugs.com) having lectured in more than 43 countries while a clinical
microbiologist in pathology (Professor), dentistry (Clinical Professor) and Graduate
...
School Education
(Adjunct Professor) for 54 years , his research emphasizing biofilms and medical devices. He has
recently focused upon micro 3-D- bio Printing of contour fitting gauzes using bio-plastics and unique
Prebiotics with Therapeutic Bacteria (Beneficial Bacteria) for chronic wound intervention (SMarT Gauze);
this integrates a common pathway, visualized through his 'Microbial Clock' and recently created Center
of Hologenomic Clinical Studies (www.globalbugs.com/Hologenomic Center) which underscores a "Dual
Citizenship" and co evolution of symbiotic microbes and human ecosystems. "Microbes Matter". His
Probiotic Solutions integrates Computer Decision Support for Probiotic (Beneficial Bacteria) Guidelines
combining AI, Artificial Intelligence and Precision Medicine, expanded recently to emphasize Chronic
Wound Care and Aging, hypothesized now as a disease.
He has over 50 publications, multiple book chapters and significant grant support. His military obligation
(1969-71)(wounds) and his sabbatical at Cardiff University, Wales, UK (2007)(oral health, biofilms) have
remained a driving catalyst. He has been a member of the American Dental Association Scientific
Advisory Committee for the last 8 years and American Society of Microbiology for 54 years.
As Faculty at 3 national (Northeastern Ohio Universities College of Medicine, Rutgers University and
West Virginia University) and 2 international Universities ( National University of Singapore and Cardiff
University) during his career , he has received multiple Alumni and University awards for research and
Student Mentoring ; retiring from West Virginia University in 2013 after 23 years as Professor Emeritus
, he presently is expanding his research/teaching utilizing the advanced resources of the Allegheny
Health Network (Center of Excellence in Biofilm Research) and Carnegie -Mellon University, Pittsburg,
PA, and Mass. Gen. Hospital (Dept. of Anesthesia and Critical Care) with Harvard University, Boston,
MA, all under the umbrella of his Global Microbiology Consulting. (GMC) (www.globalbugs.com)

Glenn is a Senior Vice President at Cempra Inc in Chapel Hill, USA. He is trained in medical microbiology and infectious diseases and almost 30 of pharmaceutical industry experience in various areas including clinical research, commercialization, scientific communications
...
including publication planning, strategic drug development, life cycle management and global launch programs. Glenn has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. He later worked for Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a team to support the launch of fidaxomicin (Dificid) the first new antibiotic for C difficile in over 20 years. Glenn is a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering as well as the Anaerobe Society. He is also past Chair of the ACCP Chest Infection Network and a member of the ACCP Executive Council of Networks. In 2009 Glenn was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. Glenn is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.

Radhakrishna Tirumalai, PhD US Pharmacopeial Convention Dr. Tirumalai has been at the USP since 2003 and is currently a Principal Scientific Liaison in the Global Science and Standards Division. He is the Staff Liaison to the USP Expert Committees on Microbiology, and Toxicology
...
He works with industry, academia, regulatory agencies and other external Science based organizations as the USP Expert Committee liaison in the development and revision of General Chapters in these areas. Dr. Tirumalai represents USP on PDA expert task forces and committees related to Microbiology and Sterility Assurance and on AAMI expert Working groups related to Microbiology, Sterility Assurance and Biocompatibility. Dr. Tirumalai's prior industry experience encompasses process and product research and development, transfer, and product manufacturing. He has a Ph.D. degree in Biochemistry. His postdoctoral work included studies on HIV and MuLV reverse transcriptases and bacteriophage lambda integrase. He has authored numerous publications and review articles. He is a frequent speaker at conferences and has taught Pharmacopeial Microbiology courses at numerous locations globally.

Continuing Education (CME/CE) Support

Please update your information

Certificate of Attendance

Thank you for choosing LabRoots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.
Please see the CE Credits tab if you are interested in Continuing Education Credits. Otherwise, click the button below to receive your Certificate of Attendance